KZIA — KAZIA THERAPEUTICS LTD

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1075880 · Australia
Last close
$5.31
Market Cap
$60.68M
52W High
$17.40
52W Low
$4.86
ADV30
265,643
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Dec 2025 — — — — 71,112,533 69,459,980 24,645,494
Jun 2025 — — — — 6,061,000 4,345,000 14,362,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-145,609,696
Inventory
—
Receivables
$307,852
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,898,631
EBITDA
$-17,840,660
Free Cash Flow
$1,099,920
Enterprise Value
$57,488,568
Total Cash
$69,459,984
Total Debt
$98,807
Shares Out
11,426,899
Trailing EPS
$-7.68
Book Value
$2.94
ROE
-106.9%
ROA
-25.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Jun 2025 42,000 -14,217,000 -20,702,000 6,061,000 14,362,000 -8,301,000 -13,278,000
Jun 2024 2,308,000 -28,462,000 -26,778,000 21,585,000 31,602,000 -10,017,000 -9,581,000
Jun 2023 0 -24,146,000 -20,465,000 28,084,000 16,034,000 12,050,000 -15,156,000
Jun 2022 0 -25,399,000 -25,014,000 35,889,000 17,614,000 18,275,000 -22,762,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.01

Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $7.50 · spot: $5.49 · call volume: 42 · put volume: 40
Expected Move to 2027-05-21: ±$6.00 (109.29%) — implied range $-0.51 – $11.49 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
FBIO Fortress Biotech, Inc. $60.70M $1.82 —
LFVN Lifevantage Corp $60.62M $4.78 —
ACRV Acrivon Therapeutics, Inc. $61.28M $1.43 —
CRBP Corbus Pharmaceuticals Holdings, Inc. $62.03M $3.01 —
CTOR CITIUS ONCOLOGY, INC. $57.91M $0.55 —

News headlines (Yahoo Finance, 1h cache)

Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader
2026-11-12 12:00 · Yahoo
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
2026-11-05 12:00 · Yahoo
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
2026-11-02 12:00 · Yahoo
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
2026-10-29 11:00 · Yahoo
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
2026-09-22 11:30 · Yahoo
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
2026-09-09 11:30 · Yahoo
Bank of New York Mellon Corporation (BNY) Lost A Depositary Mandate
2026-09-19 22:15 · Yahoo
Reddit downgraded, Rivian upgraded: Wall Street's top analyst calls
2026-10-30 13:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.